FDA, EMA put a star CAR-T from blue­bird and Cel­gene on the VIP list

Dur­ing the last AS­CO blue­bird bio and its part­ners at Cel­gene an­gled in­to cen­ter stage with an up­date on their BC­MA-tar­get­ing CAR-T drug bb2121 for mul­ti­ple myelo­ma that wowed the can­cer crowd.

The FDA as well as Eu­ro­pean reg­u­la­tors were pay­ing at­ten­tion. To­day the two com­pa­nies an­nounced that both groups had put the pro­gram on their VIP list, with a break­through ther­a­py des­ig­na­tion right along­side PRIME sta­tus.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER